AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today ...

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

AtriCure announced the successful first-in-human AFib treatments using its novel dual-energy surgical cardiac ablation platform.

Obstructive sleep apnea is associated with increased atrial fibrillation recurrence after ablation in patients with paroxysmal atrial fibrillation.

Intracardiac echocardiography is noninferior to TEE for prevention of thromboembolic complications in patients receiving ablation for AF.

BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF ...

Pulse Biosciences today announced a collaboration aimed at using its pulsed field ablation (PFA) technology for thyroid ...

A session at the AHA Scientific Sessions 2025 focused on dilemmas related to antithrombotic therapy following catheter ablation in patients with AF.

Irregular heartbeats can signal AFib. Early detection and appropriate treatments help manage it and protect long-term heart health.

Learn more about whether Alphatec Holdings, Inc. or AtriCure, Inc. is a better investment based on AAII's A+ Investor grades, ...

Learn more about whether AtriCure, Inc. or Masimo Corporation is a better investment based on AAII's A+ Investor grades, ...

A session at the AHA Scientific Sessions 2025 focused on clinical trials related to cutting edge valve and coronary care.